Brian MacDonald's pursuit of an approved hepcidin therapy at Merganser Biotech Inc. didn't quite pan out, but that didn't stop him from taking up Atlas Venture's offer to try it once again on a different tack.
Upbeat top-line data for New York-based Iveric Bio Inc.'s phase IIb trial testing Zimura in dry age-related macular degeneration propelled the company stock (NASDAQ:ISEE) 82.8% upward in Monday's trading, a big success in a company that rebranded itself earlier this year.
Roughly 40 years after Bio-Response launched the first-ever biotech IPO, three companies priced IPOs on Friday, riding a wave of momentum that has put 2019 into second place for the most IPO money raised in a single year. Only 2018's record $10.7 billion is beyond this year's total: 54 global IPOs raising $7.98 billion.
Privately held Pepticom Ltd., of Jerusalem, completed a $5 million series A fundraising, allowing it to use artificial intelligence (AI) in helping research centers, pharma and agriculture companies discover advanced peptide-based drug candidates.
Building on the positive phase II results reported in June 2018 for pamrevlumab to treat pancreatic cancer, the first dose has been administered in Fibrogen Inc.'s phase III study in patients with unresectable locally advanced pancreatic cancer.
Despite Provention Bio Inc.'s phase IIa top-line data showing PRV-6527 in Crohn's disease did not differentiate from placebo, the company's stock was bumped back less than 1% on Tuesday as it continued to ride high after June's massive leap on heartening data about the company's type 1 diabetes trial of teplizumab.
It took newly launched Plexium Inc. CEO Kandaswamy (Swamy) Vijayan a few years to figure out where he needed to focus his creative energies. With an engineering background, he helped develop diagnostic tools. But he wanted to take the skill further.
It took Kandaswamy (Swamy) Vijayan, CEO of newly launched Plexium Inc., a few years to figure out where he needed to focus his creative energies. With an engineering background, he helped develop diagnostic tools. But he wanted to take the skill further. "For longest time, I thought diagnostics were the be all and end all," Vijayan told BioWorld MedTech.
It was at the constantly changing intersection of data science that Arsenal Biosciences Inc.'s CEO, Ken Drazan, found himself as he helped bring the company to life and to its $85 million series A fundraising.
